Radiotherapy in the Adjuvant and Advanced Setting of CSCC

Paolo Muto¹, Francesco Pastore²

¹ Radiation Oncology Unit, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale – Naples, Italy
² Radiation Oncology, Fondazione Muto Onlus - Emicenter – Naples, Italy

Key words: radiotherapy, squamous cell carcinoma, brachytherapy.

Citation: Muto P, Pastore F. Radiotherapy in the adjuvant and advanced settings of CSCC. Dermatol Pract Concept. 2021; 11(S2): e2021168S. DOI: https://doi.org/10.5826/dpc.11S2a168S

Accepted: September 22, 2021; Published: October, 2021

Copyright: ©2021 Muto and Pastore. This is an open-access article distributed under the terms of the Creative Commons Attribution License BY-NC-4.0, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.

Funding: None.

Competing interests: The authors have no conflicts of interest to disclose.

Authorship: All authors have contributed significantly to this publication.

Corresponding author: Francesco Pastore, Radiation Oncology, Fondazione Muto Onlus - Emicenter – Naples, Italy.
Email: fr.pastore@libero.it

ABSTRACT

Introduction: The use of radiotherapy for cutaneous squamous cell carcinoma (CSCC) has solid historical roots. It is used with patients who are not suitable for surgery, with patients with high-risk histological features in the adjuvant setting, and in palliative care.

Objectives: The aim of this article is to summarize and provide a radiation therapy overview on the indications, effectiveness, and potential adverse events of radiotherapy in the adjuvant and advanced setting of CSCC.

Methods: We performed a comprehensive literature review on PubMed, adopted as our biomedical literature database. Articles were selected based on their date of publication (in the last 30 years) and relevance.
Introduction

Cutaneous squamous cell carcinoma (CSCC) is the second most common type of non-melanoma skin cancer (NMSC) after basal cell carcinoma (CBCC). It arises most commonly in sun-exposed areas of the body and originates from keratinocytes in the epidermis through a carcinogenesis process [1]. As the world’s population ages, the incidence of both types of NMSC (SCC and BCC) is dramatically increasing [1]. As the world’s population ages, the incidence of both types of NMSC (SCC and BCC) is dramatically increasing [1].

Invasive CSCC (histologically characterized by the presence of infiltrating cells crossing the basement membrane) has the ability to relapse and metastasize to regional lymph nodes or distant organs and, if left untreated or if inadequately treated, can lead to extensive tissue destruction up to massive patterns of tumour infiltration. Even though the ability of CSCC to metastasize is limited, the presence of distant metastases in CSCC patients is associated with poor prognosis and a median survival of less than 2 years. For this reason, it is fundamental to perform a careful clinical and surgical evaluation, that goes hand in hand with a correct early management of all cases. Multidisciplinary management is essential in order to guide the patient towards the best possible treatment options [4]. The ultimate SCC treatment goals are complete removal of the tumor or, when this is not possible, tumor debulking, and the minimization of functional and aesthetic impairment that often, for particular anatomical areas, can be a very central issue [1]. Surgery with adequate margins is the most common treatment option for most CSCCs, but radiation therapy (RT) can be an effective non-surgical option in the definitive (inoperable patients), adjuvant (high postoperative risk), and palliative (cytoreductive, pain-relieving) setting. RT is also a tissue-preserving modality that might offer a better cosmetic and functional outcome than surgery [4].

A variety of radiation therapy techniques have been used to treat epithelial skin tumors. NMSC have historically been among the first to be irradiated since discovery of radioactivity. The appropriate radiation therapy technique depends on multiple factors, including the primary tumor’s location, the neoplasm size, the scar length (in the adjuvant setting) which may be difficult to cover with radiation planning, the surrounding anatomy (presence of organs at risk that must be preserved), and the presence of disease-affected lymph nodes that deserve to be included in the radiation field [5]. Surface electrons are typically used for primary lesions or tumor beds > 5 mm or deeper, because of their unique physical penetration features. Electrons are produced by modern linear accelerators and have a dose distribution with a peak dose near the skin surface and a rapid dose drop beyond the target. This allows adequate coverage of the disease or surgical bed and the ability to minimize side effects. Superficial X-rays, or photons, have greater physical penetration compared with surface electrons and have been used to treat deep CSCC or more advanced diseases (with or without positive nodes) [6].

This article aims to summarize the effectiveness, potential adverse events, and indications of RT in the adjuvant, advanced, and palliative setting of CSCC, performed through a thorough and broad literature review.

When is Radiotherapy Recommended?

RT is recommended as adjuvant therapy in high-risk CSCC or when surgery is excluded due to cosmetic or functional reasons [6]. RT allows treatment of anatomic sites that are difficult to manage surgically, and to achieve a good cosmetic result. This applies in particular to the head and neck (H&N) region. RT is also preferred for elderly patients (> 60 years) [7]. The dose of RT can be delivered with external beams (external beam radiation therapy (EBRT)) and by direct delivery techniques.
The goal of adjuvant radiation therapy is to reduce the risk of local or regional recurrence after surgical excision. In general, adjuvant radiation therapy is offered when the risk of recurrence is high or the likelihood of successful salvage surgery is relatively low [11]. Risk factors to look out for in CSCC include male sex, recurrent disease, neoplasms located at the center of the face, poor histologic differentiation, and deep subclinical extension. Other high-risk factors for CSCC include tumor location (lip or ear), tumors arising from scarring tissues, size > 2 cm, depth > 4 mm or Clark level ≥ IV, invasion beyond subcutaneous tissues, rapidly growing lesions, perineural invasion, desmoplasia, poor differentiation, and infiltrative margins [14]. Adjuvant radiation therapy is recommended after extensive surgical excision with close or positive margins (only if the tumor cannot be re-excised) or in the presence of high-risk factors, including perineural invasion (PNI), invasion of bone or nerves, or in case of recurrent disease after previous surgical excision or other medical therapy [15]. The rate of positive margins after excision in CSCC ranges from 5.8% to 17.6% and is influenced by the adopted technique [16,17]. Positive margins after surgery have been reported as prognostic in a study [18]. Indeed, CSCCs with a close or positive surgical margin have an increased risk of local recurrence and locoregional metastasis [19]. Postoperative RT is a treatment option for tumors with margins that are not completely excised or cannot be completely resected. In a study of CSCC of the lower lip that included tumors with a close or positive margin, the local recurrence rate was 64% for tumors with positive margins that were subsequently excised versus a 6% rate for those treated with postoperative RT [20]. PNI is an important risk factor because it has been shown to be associated with a higher risk of recurrence and a higher incidence of lymph node metastasis [18]. PNI occurs in between 2.5% and 14% of CSCCs, usually found as an incidental histologic finding. It has been linked to poor prognosis and a higher rate of metastasis and disease-specific death [14,21,22]. Extensive PNI is an indication for postoperative RT according to NCCN guidelines [23]. Postoperative RT has also been recommended for high-risk tumors.

Historically, the definition of high risk has been a matter of debate. Guidelines agree on the definition of high risk as a disease characterized by diameter > 2 cm, a thickness > 2 mm (and especially 6 mm), poor differentiation, ear or lip location, PNI, recurrence, and immunosuppression [24]. Most of the evidence regarding the role of postoperative RT in the other risk is derived from a 2009 systematic review indicating that prognosis is generally excellent as long as margins are negative and PNI is not observed, and therefore postoperative RT is not necessary if no such findings occur [25]. CSCC with cranial nerve invasion, on the other hand, represents a possible criterion for choosing to perform postoperative RT [26]. Several RT schedules have been used for adjuvant treatment of CSCC. Briefly, the proposed algorithm by the NCCN includes doses of 60-64 Gy over 6 to 7 weeks or 50 Gy over 4 weeks [23].
Radiotherapy in the Definitive Setting

Definitive primary RT represents a curative and alternative treatment strategy to surgery for CSCC. RT may be considered as primary treatment in patients who are not candidates for surgery (eg locally advanced CSCC, comorbidities, or refusal of surgery) or in cases where surgery is not feasible. This may occur when the surgical approach could result in poor functional outcomes or be disfiguring, as in large CSCC lesions located on the face (eg eyelids, nose, and lips) or large lesions on the ear, forehead, or scalp [13]. No prospective randomized trials comparing the efficacy of primary RT in local tumor control and patient survival compared with other local therapy modalities are available. A mean local recurrence rate of 6.4% was reported in a meta-analysis analyzing 1018 CSSCs, including 14 observational RT studies [1]. Also in the exclusive setting, RT dose can be delivered as either EBRT or BRT. EBRT can use both photons and electrons, with deeply penetrating energies in the range of 4-10 MV. Treatment can be administered to a small surface area (eg the nasal wing) or a large complex volume (eg the entire scalp or base of the skull). The total prescribed dose and fractionation should reflect differences in radiobiologic efficacy between radiation modalities. Briefly, doses of 45-50 Gy in fractions of 2.5-3 Gy are recommended for tumors < 2 cm and doses of 60-66 Gy in fractions of 2 Gy or 50-60 Gy in fractions of 2.5 Gy for tumors > 2 cm [1].

RT is an overall safe procedure, although it can be associated with both acute and late toxicities. The most frequent acute toxicity may consist of acute, often erosive dermatitis, while late onset chronic depigmentation and telangiectasias are more often seen. Moreover, RT should not be recommended in younger (< 60 years old) patients because chronic toxicity becomes more visible with age. Higher doses per fraction lead to higher rates of late toxicity [27]. Therefore, accelerated fractionation schemes (acceleration means radiation treatment in which the total dose of radiation is given over a shorter period of time compared to standard radiation therapy) should be reserved for elderly and frail patients, or when the cosmetic outcome is less important. The volume to be irradiated in CSCCs represents the visible disease gross tumor volume (GTV) associated with microscopic disease and possible leakage pathways. The prescribed dose should therefore include all visible tumors plus an appropriate variable margin (clinical target volume), sparing surrounding healthy structures as much as possible [28,29]. Dosimetry and technical details should be monitored by a certified radiation oncologist, for some difficult anatomical sites there is the risk to undertreat some CSCC. RT may be combined with systemic therapies including chemotherapy (chemoradiation) or cetuximab in more advanced cases (for H/N tumours). Age is a very important issue for dose/fractionation decisions: as mentioned above, there are multiple dose fractionation schedules, but in patients < 50 years old RT fraction sizes of 2-2.5 Gy are delivered over a period of 4-5 weeks, with the aim of achieving the best long-term results (heal and cosmetic outcome) [30]. When deciding on the number of fractions to prescribe for an appropriate course of radiotherapy, age must be considered together with the patient’s medical co-morbidity, performance status, and preference. In older (70-80 years old) patients it could be useful to decrease the total duration of treatment using daily RT fraction sizes of 3-4 Gy over a period of 2-3 weeks (40-45 Gy in 10-15 fractions). In elderly patients (> 80 years old) less frequent (1 to 3 times per week) and larger fraction sizes are recommended, such as 5-7 Gy in 5 to 6 fractions [31]. Hypofractionated RT delivered 2-3 times a week or once weekly is a highly effective option with tolerable treatment-related toxicity (Figures 1 and 2). Two recent systematic reviews of hypofractionated RT reported durable local control rates of over 90% and acceptable side effects [32]. In a systematic review comprising 40 relevant publications (external beam RT and brachytherapy included) of over 12 000 NMSC (24% SCC), local recurrence rates did not exceed 7.9%. The authors concluded that hypofractionated RT does not confer no obvious disadvantage in local control when compared with traditional more protracted RT schedules [33]. RT could have also an important role in palliative setting for bleeding tumors, to reduce disfiguring or symptomatic neoplasms: the most used schedules are 30 Gy in 10 daily fractions or 20 Gy in 5 fractions.

Brachytherapy

Brachytherapy for cutaneous neoplasms has solid historical roots (with the first documented cases in 1896) [34]. Interest in the use of brachytherapy for skin cancers has decreased with the development of better surgical techniques such as Mohs surgery, and its application in skin cancer has declined
significantly over the years. The introduction of the high-dose-rate afterloading technique and electronic brachytherapy has renewed interest in the role of brachytherapy in CSCC. Compared with external beam RT, high-dose-rate brachytherapy demonstrates some advantages, such as delivery of a high dose of radiation in the clinical target volume/planning target volume, rapid dose decrease at the periphery of the target, optimal sparing of normal tissue in sensitive structures, shorter treatment time, and use of a hypofractionated pathway. Cutaneous brachytherapy is advantageous especially in curved surfaces and should be considered instead of external beam radiation therapy (if surgical excision is not possible) in areas of poor vascularization, such as the back of the hands or feet or lower legs. It can be administered, for example, in a superficial technique using dermal applicators with 192iridium [35].

Interstitial brachytherapy is another option to deliver high dose radiation rate in thicker (above 5 mm) skin lesions with catheters to be inserted under anaesthesia directly into the lesion or surgical bed in the adjuvant setting [36]. Electronic brachytherapy is a new technique of RT based on a miniaturised X-ray source that allows to treat small and flat surfaced CSCC, [37, 38] and has attracted considerable interest in recent years in the management of CSCC [39]. Although preliminary data on the use of electronic brachytherapy in CSCC are promising, there is a lack of scientific work designed for direct comparison with external beam RT or radionuclide brachytherapy. Because this is a relatively new scientific scenario, long-term follow-up data are also missing.

The American Brachytherapy Society consensus statement does not endorse the use of electronic brachytherapy outside of prospective clinical studies. [40].

RT Planning

The main treatment planning modality in a modern radiation therapy department is based on computed tomography. Computed tomography is used to define the clinical target and organs at risk in photon and electron treatment (Figures 3 and 4). Integration with MRI imaging (for increased

Figure 2. Post RT treatment for a CSCC.

Figure 3. Treatment electron planning for a CSCC.

Figure 4. Treatment electron planning for a CSCC.
reliability for soft tissue) or PET (for biological assessment of disease) is often necessary. Radiation therapy results depend on accurate coverage of a target volume with appropriate margins. Margins that are too narrow can lead to local failure and margins that are too wide can increase radiation therapy-related morbidity. Delineating a target volume could be challenging, particularly in superficial and small CSCC, where the spatial resolution of computed tomography limits the visualization of any skin lesions. Multidisciplinary evaluation with the dermatologist (dermoscopic imaging) or surgeon (for surgical scar margins) is essential for the assessment of such targets [41]. In skin RT, the use of computed tomography-based planning is also linked to cases of larger and deeply invading CSCC, nodal basin RT, skin brachytherapy planning and in select palliative settings. After the clinical target and organs at risk delineation, a personalized plan is built up by the certified radiation oncologist in synergy with the medical physicist, respecting the dose limits of any organ at risk to minimize the side effects of radiation treatment.

Conclusions

Radiotherapy could be an optimal therapeutic option for CSCC. It could be used for non-surgical candidates as exclusive therapy, in adjuvant high risk patients or to decrease pain and bleeding. Several dose schedules and techniques have been proposed both for EBRT (External beam radiotherapy) than for BRT (Brachytherapy). Multidisciplinary assessment is a main issue in this subset of patients.

References

1. Lansbury L, Bath-Hextall F, Perkins W, Stanton W, Leonard-Bee J. Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies. BMJ. 2013;34:6153. DOI: 10.1136/bmj.g191270.
2. Lomas A, Leonard-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;166(5):1069–1080. DOI: 10.1111/j.1365-2133.2012.10830.x. PMID: 22251204.
3. Kallini JR, Hamed N, Khachemoune A. Squamous cell carcinoma of the skin: epidemiology, classification, management, and novel trends. Int J Dermatol.2015;54(2):130–140. DOI: 10.1111/ijd.12553.PMID: 25428226.
4. Veness MJ, Delshaj D, Barnes EA, Bezugly A, Rembielak A. Current Role of Radiotherapy in Non-melanoma Skin Cancer. Clin Oncol (R Coll Radiol).2019;31(11):749–758. DOI: 10.1016/j.clon.2019.08.004.PMID: 31447088.
5. [5] Kwan W, Wilson D, Moravan V.Radiotherapy for locally advanced basal and squamous cell carcinomas of the skin. Int J Radiat Oncol Biol Phys. 2004;60(2):406–411. DOI: 10.1016/j.ijrobp.2004.03.006.PMID: 15380573.
6. Rong Y, Zuo L, Shang L, Bazan JG. Radiotherapy treatment for nonmelanoma skin cancer. Expert Rev Anticancer Ther.2015;15(7):765–776.DOI: 10.1586/14737140.2015.1042865.PMID: 25953383.
7. Lee DA, Miller SJ. Nonmelanoma skin cancer. Facial Plast Surg Clin North Am. 2009;17(3):309–324. DOI: 10.1016/j.fsc.2009.04.004.PMID: 19698913.
8. Strom T, Harrison LB. Radiotherapy for management of basal and squamous cell carcinoma. Currr Probl Cancer. 2015;39(4):237–247. DOI: 10.1016/j.jcurpprcancer.2015.07.003. PMID: 26364698.
9. Kramkime N, Dendale R, Rolle S, Zefkili S, Fourquet A, Kirova YM. Management of advanced non-melanoma skin cancers using helical tomotherapy. J Eur Acad Dermatol Venereol. 2014;28(5):641–650. DOI: 10.1111/jdv.2152.PMID: 23560525.
10. Gb F, Christie D, Spelman LJ, Supranowicz MJ, Sinclair RJ. Can Modern Radiotherapy be used for Extensive Skin Field Cancerisation - An Update on Current Treatment Options. Biomedical Journal of Scientific & Technical Research. 2018;4(1):3719–3726. DOI:10.26717/BJSJR.2018.04.009998.
11. Mendenhall WM, Amdur RJ, Hinerman RW, Cognetta AB, Mendenhall P. Radiotherapy for cutaneous squamous and basal cell carcinomas of the head and neck. Laryngoscope. 2009;119(10):1994–1999. DOI: 10.1002/lary.20608. PMID: 19688856.
12. Pampena R et al. Orthovoltage radiotherapy for nonmelanoma skin cancer (NMSC): Comparison between 2 different schedules. J Am Acad Dermatol. 2016;74(2):341–347. DOI: 10.1016/j.jaad.2015.09.031.PMID: 26589877.
13. Stratigos AJ et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. European Journal of Cancer. 2020;128:83–102. DOI: 10.1016/j.ejca.2020.01.008. PMID: 32113942.
14. Thompson AK, Kelley BF, Prokop LJ, Murad MH, Baum CL. Risk Factors for Cutaneous Squamous Cell Carcinoma Recurrence, Metastasis, and Disease-Specific Death: A Systematic Review and Meta-analysis. JAMA Dermatol.2016;152(4):419–428. DOI: 10.1001/jamadermatol.2015.4994.PMID: 26762219.
15. Han A, Ratner D. What is the role of adjuvant radiotherapy in the treatment of cutaneous squamous cell carcinoma with perineural invasion? Cancer. 2007;109(6):1053–1059. DOI: 10.1002/cncr.222509. PMID: 17279578.
16. Khan AA et al. Guidelines for the excision of cutaneous squamous cell cancers in the United Kingdom: the best cut is the deepest. J Plast Reconstr Aesthet Surg. 2013;66(4):467–471. DOI: 10.1016/j.bjsps.2012.12.016. PMID: 23352886.
17. Mirshams M, Razzaghi M, Noormohammadpour P, Naraghi Z, Kamyab K, Sabouri Rad S. Incidence of incomplete excision in surgically treated cutaneous squamous cell carcinoma and identification of the related risk factors. Acta Med Iran. 2011;49(12):806–809.
18. Cañuto J, Jaka A, Toll A. The Value of Adjuvant Radiotherapy in Cutaneous Squamous Cell Carcinoma: A Review. Actas Dermosiﬁlotrg. 2018;109(6):476–484. DOI: 10.1016/j.ad.2018.03.007. PMID: 29759308.
19. Housman TS et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol., 2003;48(3):423–429. DOI: 10.1067/mjd.2003.186. PMID: 12637924.
20. Babington S, Veness MJ, Cakir B, Gebski VJ, Morgan GJ. Squamous cell carcinoma of the lip: is there a role for adjuvant ra-
Radiotherapy in improving local control following incomplete or inadequate excision? ANZ J Surg. 2003; 73(8):621–625. DOI: 10.1046/j.1445-2197.2003.01-1-02710.x. PMID: 12887333.

21. Carter JB, Johnson MM, Chua TL, Karia PS, Schults CD. Outcomes of primary cutaneous squamous cell carcinoma with perineural invasion: an 11-year cohort study. JAMA Dermatol. 2013;149(1):35–41. DOI: 10.1001/jamadermatol.2013.746. PMID: 23324754.

22. Rowe DE, Carroll RJ, Day CL. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol. 1992;26(6):976–990. DOI: 10.1016/0190-9622(92)70144-5.

23. NCCN guidelines. NCCN guidelines squamous cell carcinoma. Accessed: June 2021. www.nccn.org in.

24. Martorell-Calatayud A, Sanmartín Jimenez O, Cruz Mojarrieta J, Guilleón Barona C. Cutaneous squamous cell carcinoma: defining the high-risk variant. Actas Dermosifiliogr. 2013;104(5):367–379. DOI: 10.1016/j.adengl.2011.12.012. PMID: 23683506.

25. [25] Jambusaria-Pahlajani A, Miller CJ, Quon H, Smith N, Klein RQ, Schults CD. Surgical monotherapy versus surgery plus adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma: a systematic review of outcomes. Dermatol Surg. 2009;35(4):574–585. DOI: 10.1111/j.1524-4725.2009.01095.x. PMID: 19415791.

26. Raza SM et al. Nonmelanoma cutaneous cancers involving the skull base: outcomes of aggressive multimodal management. J Neurosurg. 2015;123(3):781–788. DOI: 10.3171/2014.10. jns141037. PMID: 25909577.

27. Cuperus E, Leguit R, Albregts M, Toonstra J. Post radiation skin angiosarcomas. A review of this late effect of radiotherapy. Eur J Dermatol. 2013;23(6):749–757. DOI: 10.1684/ejd.2013.2106. PMID: 24153098.

28. Mierzwka ML. Radiotherapy for Skin Cancers of the Face, Head, and Neck. Facial Plast Surg Clin North Am. 2019;27(1):131–138. DOI: 10.1016/j.fsc.2018.08.005. PMID: 30420066.

29. Garbutcheon-Singh KB, Veness MJ. The role of radiotherapy in the management of non-melanoma skin cancer. Australas J Dermatol. 2019;60(4):265–272. DOI: 10.1111/ajd.13025. PMID: 30931531.

30. Buchanan MA, Levin B, Veness M. Non-melanoma Skin Cancer: Primary Non-surgical Therapies and Prevention Strategies. In: Non-melanoma Skin Cancer of the Head and Neck. Springer India. 2015. pp 37–51. DOI: 10.1007/978-81-322-2497-6_4. PMID: 26995368.

31. Veness M. Hypofractionated radiotherapy in older patients with non-melanoma skin cancer: Less is better. Australas J Dermatol. 2018;59(2):124–127. DOI: 10.1111/ajd.12609. PMID: 28294289.

32. Gunaratne DA, Veness MJ. Efficacy of hypofractionated radiotherapy in patients with non-melanoma skin cancer: Results of a systematic review. J Med Imaging Radiat Oncol. 2018;62(3):401–411. DOI: 10.1111/j.1575-9485.12718. PMID: 29254319.

33. Zaorsky NG, Lee CT, Zhang E, Keith SW, Galloway TJ. Hypofractionated radiation therapy for basal and squamous cell skin cancer: A meta-analysis. Radiother Oncol. 2017;125(1):13–20. DOI: 10.1016/j.radonc.2017.08.011. PMID: 28843727.

34. Gupta. Brachytherapy - Past, Present And Future. undefined. 1995. Accessed: May 23, 2021. /paper/Brachytherapy-Past%2C-Present-And-Future-Gupta/2d86234c7db52e9ecb3386f5ccf-hb96205e82703; https://inis.iaea.org/search/search.aspx?orig_q=RN:28030553.

35. Sabbas AM, Kulidzhanov FG, Presser J, Hayes MK, Nori D. HDR brachytherapy with surface applicators: technical considerations and dosimetry. Technol Cancer Res Treat. 2004; 3(3):259–267DOI: 10.1177/13330460400300304. PMID: 15161319.

36. Ouhib Z et al. Aspects of dosimetry and clinical practice of skin brachytherapy: The American Brachytherapy Society working group report. Brachytherapy. 2015;14(6):840–858. DOI: 10.1016/j.brachy.2015.06.005. PMID: 26319367.

37. Bhatnagar A. Nonmelanoma skin cancer treated with electronic brachytherapy: results at 1 year. Brachytherapy. 2013;12(2):134–140. DOI: 10.1016/j.brachy.2012.08.003. PMID: 23312675.

38. Ballester-Sánchez R et al. Electronic brachytherapy for superficial and nodular basal cell carcinoma: a report of two prospective pilot trials using different doses. J Contemp Brachythera.py. 2016;8(1):48–55. DOI: 10.5114/jcb.2016.57531. PMID: 26985197.

39. Gunaratne DA, Veness MJ. Efficacy of hypofractionated radiotherapy in patients with non-melanoma skin cancer: Results of a systematic review. J Med Imaging Radiat Oncol. 2018;62(3):401–411. DOI: 10.1111/j.1575-9485.12718. PMID: 29254319.

40. Tom MC et al. The American Brachytherapy Society consensus statement for electronic brachytherapy. Brachytherapy. 2019;18(3):292–298.DOI: 10.1016/j.brachy.2018.10.006. PMID: 30497939.

41. Khan L et al. Recommendations for CTV margins in radiotherapy planning for non melanoma skin cancer. Radiother Oncol. 2012;104(2):263–266. DOI: 10.1016/j.radonc.2012.06.013. PMID: 22857860.